Convection Enhanced Delivery in the Setting of High-Grade Gliomas

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2021 Apr 30

PMID 33921157

Citations 8

Authors

Chibueze D Nwagwu

Amanda V Immidisetti

Michael Y Jiang

Oluwasegun Adeagbo

David C Adamson

Anne-Marie Carbonell

Affiliations

Soon will be listed here.

Abstract

Development of effective treatments for high-grade glioma (HGG) is hampered by (1) the blood-brain barrier (BBB), (2) an infiltrative growth pattern, (3) rapid development of therapeutic resistance, and, in many cases, (4) dose-limiting toxicity due to systemic exposure. Convection-enhanced delivery (CED) has the potential to significantly limit systemic toxicity and increase therapeutic index by directly delivering homogenous drug concentrations to the site of disease. In this review, we present clinical experiences and preclinical developments of CED in the setting of high-grade gliomas.

Citing Articles

Toxoplasma gondii infection supports the infiltration of T cells into brain tumors.

Nguyen Y, Sibley L, Przanowski P, Zhao X, Kovacs M, Wang S J Neuroimmunol. 2024; 393:578402.

PMID: 38996717 PMC: 11318612. DOI: 10.1016/j.jneuroim.2024.578402.

Nonclinical pharmacodynamics of boron neutron capture therapy using direct intratumoral administration of a folate receptor targeting novel boron carrier.

Tsujino K, Kashiwagi H, Nishimura K, Fujikawa Y, Kayama R, Fukuo Y Neurooncol Adv. 2024; 6(1):vdae062.

PMID: 38770220 PMC: 11102930. DOI: 10.1093/noajnl/vdae062.

Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.

Jain S, Griffith J, Porath K, Rathi S, Le J, Pasa T Clin Cancer Res. 2024; 30(15):3287-3297.

PMID: 38743766 PMC: 11292202. DOI: 10.1158/1078-0432.CCR-24-0426.

Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review.

Saito A, Kitayama J, Nagai R, Aizawa K Pharmaceutics. 2023; 15(6).

PMID: 37376112 PMC: 10301590. DOI: 10.3390/pharmaceutics15061664.

Advantageous Reactivity of Unstable Metal Complexes: Potential Applications of Metal-Based Anticancer Drugs for Intratumoral Injections.

Levina A, Crans D, Lay P Pharmaceutics. 2022; 14(4).

PMID: 35456624 PMC: 9026487. DOI: 10.3390/pharmaceutics14040790.

References

Vogelbaum M, Sampson J, Kunwar S, Chang S, Shaffrey M, Asher A . Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results. Neurosurgery. 2007; 61(5):1031-7. DOI: 10.1227/01.neu.0000303199.77370.9e. View

Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G . Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010; 12(8):871-81. PMC: 2940677. DOI: 10.1093/neuonc/nop054. View

Stine C, Munson J . Convection-Enhanced Delivery: Connection to and Impact of Interstitial Fluid Flow. Front Oncol. 2019; 9:966. PMC: 6783516. DOI: 10.3389/fonc.2019.00966. View

Parney I, Kunwar S, McDermott M, Berger M, Prados M, Cha S . Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg. 2005; 102(2):267-75. DOI: 10.3171/jns.2005.102.2.0267. View

Bruce J, Fine R, Canoll P, Yun J, Kennedy B, Rosenfeld S . Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 2011; 69(6):1272-9. PMC: 4940854. DOI: 10.1227/NEU.0b013e3182233e24. View

Faraji A, Jaquins-Gerstl A, Valenta A, Ou Y, Weber S . Electrokinetic Convection-Enhanced Delivery of Solutes to the Brain. ACS Chem Neurosci. 2020; 11(14):2085-2093. PMC: 11059855. DOI: 10.1021/acschemneuro.0c00037. View

Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A . Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides. 2007; 17(2):201-12. DOI: 10.1089/oli.2006.0053. View

Segarra M, Aburto M, Acker-Palmer A . Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis. Trends Neurosci. 2021; 44(5):393-405. DOI: 10.1016/j.tins.2020.12.002. View

Zhan W, Rodriguez Y Baena F, Dini D . Effect of tissue permeability and drug diffusion anisotropy on convection-enhanced delivery. Drug Deliv. 2019; 26(1):773-781. PMC: 6711026. DOI: 10.1080/10717544.2019.1639844. View

10.

Johnson V, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield E . Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg. 1989; 70(2):240-8. DOI: 10.3171/jns.1989.70.2.0240. View

11.

Weaver M, Laske D . Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003; 65(1):3-13. DOI: 10.1023/a:1026246500788. View

12.

Shi M, Anantha M, Wehbe M, Bally M, Fortin D, Roy L . Liposomal formulations of carboplatin injected by convection-enhanced delivery increases the median survival time of F98 glioma bearing rats. J Nanobiotechnology. 2018; 16(1):77. PMC: 6172733. DOI: 10.1186/s12951-018-0404-8. View

13.

Tanner P, Holtmannspotter M, Tonn J, Goldbrunner R . Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note. Neurosurgery. 2007; 61(4):E880-2. DOI: 10.1227/01.NEU.0000298922.77921.F2. View

14.

Vogelbaum M, Brewer C, Barnett G, Mohammadi A, Peereboom D, Ahluwalia M . First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg. 2018; 130(2):476-485. DOI: 10.3171/2017.10.JNS171845. View

15.

DAmico R, Neira J, Yun J, Alexiades N, Banu M, Englander Z . Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model. J Neurosurg. 2019; 133(3):614-623. PMC: 7227320. DOI: 10.3171/2019.3.JNS1963. View

16.

Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M . 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol. 2000; 53(1):53-7. DOI: 10.1016/s0167-8140(99)00117-6. View

17.

Shi M, Fortin D, Paquette B, Sanche L . Convection-enhancement delivery of liposomal formulation of oxaliplatin shows less toxicity than oxaliplatin yet maintains a similar median survival time in F98 glioma-bearing rat model. Invest New Drugs. 2016; 34(3):269-76. PMC: 5173352. DOI: 10.1007/s10637-016-0340-0. View

18.

Rousseau J, Barth R, Fernandez M, Adam J, Balosso J, Esteve F . Efficacy of intracerebral delivery of cisplatin in combination with photon irradiation for treatment of brain tumors. J Neurooncol. 2009; 98(3):287-95. PMC: 3375241. DOI: 10.1007/s11060-009-0074-3. View

19.

Raghavan R, Brady M, Rodriguez-Ponce M, Hartlep A, Pedain C, Sampson J . Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus. 2006; 20(4):E12. DOI: 10.3171/foc.2006.20.4.7. View

20.

Sampson J, Archer G, Pedain C, Wembacher-Schroder E, Westphal M, Kunwar S . Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2009; 113(2):301-9. DOI: 10.3171/2009.11.JNS091052. View